Portal de investigação
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction. - A Post Hoc Analysis of the EMPEROR-Preserved Trial.
Unidades de investigação
Abstract
Filiações
Filiações não disponíveis
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Citar a publicação
Butler J,Usman MS,Filippatos G,Ferreira JP,Böhm M,Brueckmann M,Januzzi JL,Kaul S,Piña IL,Ponikowski P,Senni M,Sumin M,Verma S,Zaremba L,Pocock SJ,Packer M,Anker S. Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction. - A Post Hoc Analysis of the EMPEROR-Preserved Trial. JAMA Cardiol. 2023. 8. (7):p. 640-640. IF:24,000. (1).
